Invivyd, Inc. (IVVD), a biopharmaceutical company, Wednesday announced that during its CANOPY phase 3 trial Pemivibart conferred an 84 percent reduction in the risk of becoming sick from COVID-19, compared to placebo. The formal evaluation was for six months, with a follow up of further six months.
Pemgarda or pemivibart is a half-life extended investigational monoclonal antibody.
Meanwhile, FDA acknowledged that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain.
Invivyd said it plans to engage FDA shortly on an expedited pathway to develop scalable COVID-19 prevention and treatment options.
Invivyed, in a follow-on said FDA leadership correctly identified gaps in the modern understanding of COVID-19 vaccine booster efficacy and provided a mechanism to resolve those gaps and move forward.
CANOPY Phase 3 clinical trial included a placebo-controlled, randomized cohort of average Americans who are at risk of acquiring SARS-CoV-2 due to regular unmasked face-to-face interactions in indoor settings.
According to Invivyd, Pemgarda has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, and it targets the SARS-CoV-2 spike protein receptor binding domain thereby inhibiting virus attachment to the human ACE2 receptor on host cells.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.